https://orcid.org/0000-0003-2771-9579
References
- FDA. Biosimilars. 2022. [cited 2022 Apr 13]. Available from: https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/biosimilars.
- Pivot X, Pegram M, Cortes J, Lüftner D, Lyman GH, Curigliano G, et al. Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2–positive breast cancer. Eur J Cancer. 2019;120:1–9. doi:https://doi.org/10.1016/j.ejca.2019.07.015.
- Lüftner D, Lyman GH, Gonçalves J, Pivot X, Seo M. Biologic drug quality assurance to optimize HER2+ breast cancer treatment: insights from development of the trastuzumab biosimilar SB3. Target Oncol. 2020;15(4):467–75. doi:https://doi.org/10.1007/s11523-020-00742-w.
- Lyman GH. How biosimilars will impact costs and care in oncology. Clin Adv Hematol Oncol. 2019;17(10):544–7.
- Lyman GH, Balaban E, Diaz M, Ferris A, Tsao A, Voest E, et al. American Society of Clinical Oncology statement: biosimilars in oncology. J Clin Oncol. 2018;36(12):1260–5. doi:https://doi.org/10.1200/JCO.2017.77.4893.
- Williamson C, Berger L, Sullivan TP, Crawford J, Lyman GH. Addressing oncologists’ gaps in the use of biosimilar products. Am J Manag Care. 2019;25(6 Spec No):SP188–SP191.
- Denduluri N, Somerfield MR, Chavez-MacGregor M, Comander AH, Dayao Z, Eisen A, et al. Selection of optimal adjuvant chemotherapy and targeted therapy for early breast cancer: ASCO guideline update. JCO. 2021;39(6):685–93. doi:https://doi.org/10.1200/JCO.20.02510.
- Nahleh Z, Lyman GH, Schilsky RL, Peterson DE, Tagawa ST, Chavez-MacGregor M, et al. Use of biosimilar medications in oncology. JCO Oncol Pract. 2022;18(3):177–86. doi:https://doi.org/10.1200/OP.21.00771.
- Lyman GH, Kuderer N. Rumors of the death of biosimilars have been greatly exaggerated. Cancer Invest. 2019;37(8):325–26.
- Papautsky EL, Carlson M, Lustberg M. The patient-centered paradox: a US-based survey of physician- and patient-reported experiences with biosimilar trastuzumab. San Antonio, TX: San Antonio Breast Cancer Symposium; 2021.
- Papautsky EL, Patterson ES. Patients are knowledge workers in the clinical information space. Appl Clin Inform. 2021;12(1):133–40. doi:https://doi.org/10.1055/s-0041-1723022.
- Papautsky EL, Crandall B, Grome A, Greenberg JM. A case study of source triangulation: using artifacts as knowledge elicitation tools in healthcare space design. J Cogn Eng Decis Mak. 2015;9(4):347–58. doi:https://doi.org/10.1177/1555343415613720.
- Papautsky EL, Carlson M, Johnson SM, Montague H, Attai DJ, Lustberg MB. Characterizing experiences of non-medical switching to trastuzumab biosimilars using data from internet-based surveys with US-based oncologists and breast cancer patients. Breast Cancer Res Treat. 2022;1–9.